ReviewFEBS open bio2026
Fluorination: A strategy to tune the interactions of molecules and nanoscale systems with biological matter.
Review in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Fluorination has become a key molecular engineering strategy in medicinal chemistry and nanomedicine, enabling the fine tuning of the physicochemical and biological properties of therapeutic molecules and drug delivery systems. The unique characteristics of fluorine, including its small steric footprint, high electronegativity, and exceptional strength of the C-F bond, enhance metabolic stability, modulate lipophilicity and acidity, and improve pharmacokinetic profiles. Beyond these well-established effects, fluorination has emerged as a tool for controlling the assembly and biological behavior of nanocarriers. Fluorinated biomolecules, polymers, dendrimers, and lipid-based systems often display improved colloidal stability, reduced nonspecific protein adsorption, enhanced cellular uptake, and efficient endosomal escape, ultimately leading to superior intracellular delivery of nucleic acids, proteins, and other therapeutic cargoes. Here we summarize recent advances in the fluorination of both therapeutic cargoes and delivery carriers, emphasizing how different fluorination strategies, including single fluorine atoms, trifluoromethyl groups, linear perfluoroalkyl chains, and emerging short branched fluorinated motifs, can be exploited to optimize drug delivery performance. Attention is devoted to the relationship between fluorinated molecular architectures, self-assembly, and bio-nano interactions that govern biological activity. Furthermore, the advantages and limitations of current fluorination approaches are discussed. Finally, we highlight the need for a deeper mechanistic understanding of how fluorinated moieties interact with proteins and biological membranes. Advanced physicochemical techniques, including neutron and X-ray scattering and reflectometry, are expected to provide fundamental insights into these processes, enabling the rational design of more effective, safer, and environmentally sustainable fluorinated therapeutics and nanomedicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.